Skip to main content

White paper

Clinicogenomics: Linked data advances research

Since the human genome was first sequenced life sciences researchers have sought to use this information to improve health. But they soon discovered that DNA sequence data alone has limited value when trying to understand the effects of genetic variation on health.

Today, researchers are increasingly linking genomic data to rich, longitudinal clinical information — a practice that yields clinicogenomics data. The field of clinicogenomics is unlocking novel insights to better understand diseases and to guide drug discovery, development and commercialization.

The study of clinicogenomics across large, diverse populations can help researchers:

  • Better understand disease pathways
  • Discover novel therapeutic targets
  • Identify variation in disease onset and progression
  • Evaluate drug safety and efficacy

Our latest white paper details the foundations of genomics-driven research and the sources of clinicogenomics data. It also highlights the ways clinicogenomics data can enhance clinical trials and fuel discovery and development of safer, more effective drugs.

Related healthcare insights

Video

Quick and safe digital specialty pharmacy service

Optum Specialty Pharmacy leverages specialized expertise and resources with flexibility, delivering personalized care that drives better outcomes.

Article

How real-world evidence can inform pharma strategies in 2025

Health economics and outcomes research (HEOR) can play a key role in helping the life sciences industry improve patient outcomes.

Article

4 ways small biopharma can harness RWD

Small and emerging biopharma companies are already having an impact on the industry. Learn how RWD can enhance the ability to innovate.